Keeping a critical eye on the science and the regulation of oral drug absorption: A review

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3018-3036

  Macheras, Panos ^a   Karalis, Vangelis ^a   Valsami, Georgia ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

ADME; BCS; BDDCS; Bioavailability; Bioequivalence; Gastrointestinal transit; Oral absorption; Permeability; Solubility

Indexed keywords

CARBAMAZEPINE; MULTIDRUG RESISTANCE PROTEIN 2; POLITEF; THEOPHYLLINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; HUMAN; HYDRODYNAMICS; MAXIMUM PLASMA CONCENTRATION; ORAL DRUG ADMINISTRATION; REGULATORY MECHANISM; SCIENCE; TABLET;

ADME; BCS; BDDCS; BIOAVAILABILITY; BIOEQUIVALENCE; GASTROINTESTINAL TRANSIT; ORAL ABSORPTION; PERMEABILITY; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOPHARMACEUTICS; DRUG AND NARCOTIC CONTROL; EUROPE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MODELS, BIOLOGICAL; PERMEABILITY; SOLUBILITY; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 84881616061     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23534     Document Type: Article

References (218)

1. Macheras P, Iliadis A. 2006. Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: Homogeneous and heterogeneous approaches. New York: Springer.
2. Noyes AA, Whitney WR. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934.
3. Dokoumetzidis A, Macheras P. 2006. A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System. Int J Pharm 321:1-11.
4. Brodie B, Hogben C. 1957. Some physico-chemical factors in drug action. J Pharm Pharmacol 9:345-380.
5. Shore P, Brodie B, Hogben C. 1957. The gastric secretion of drugs: A pH partition hypothesis. J Pharmacol Exp Ther 119:361-369.
6. Shanker LS, Tocco DJ, Brodie BB, Hogben CAM. 1958. Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther 123:81-88.
7. Hogben C, Tocco D, Brodie B, Schanker L. 1959. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 125:275-282.
8. Al-Awqati Q. 1999. One hundred years of membrane permeability: Does Overton still rule? Nat Cell Biol 1:E201-202.
9. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. International transporter consortium. Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
10. Edwards LJ. 1951. The dissolution and diffusion of aspirin in aqueous media. Trans Faraday Soc 47:1191-1210.
11. Levy G, Hayes B. 1960. Physiochemical basis of the buffered acetylsalicylic acid controversy. N Engl J Med 262:1053-1058. [Comment in Levy G, Hayes B. 1960. Physiochemical basis of the buffered acetylsalicylic acid controversy. N Engl J Med 262:1053-1058-The backstory. 2011. AAPS J 13:320-322.]
12. Nelson E. 1957. Solution rate of theophylline salts and effects from oral administration. J Am Pharm Assoc 46:607-614.
13. Levy G. 1961. Comparison of dissolution and absorption rates of different commercial aspirin tablets. J Pharm Sci 50:388-392.
14. Levy G. 1963. Effect of certain tablet formulation factors on dissolution rate of the active ingredient I. J Pharm Sci 52:1039-1046.
15. Levy G. 1963. Effect of certain tablet formulation factors on dissolution rate of the active ingredient II. J Pharm Sci 52:1047-1051.
16. Levy G. 1965. Development of in vitro dissolution tests which correlate quantitatively with dissolution rate-limited drug absorption in man. J Pharm Sci 54:1719-1722.
17. Federal Register. 1977. Bioavailability and bioequivalence requirements. Federal Register 42:1624-1653.
18. Wagner JG. 1961. Biopharmaceutics: Absorption aspects. J Pharm Sci 50:359-387.
19. United States Pharmacopeia (USP) 18. U.S. Pharmacopoeial Convention. Rockville, MD.
20. Dressman JB, Amidon GL, Fleisher D. 1985. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J Pharm Sci 74:588-589.
21. Macheras P, Symillides M. 1989. Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept. Biopharm Drug Dispos 10:43-53.
22. Sinko PJ, Leesman GD, Amidon GL. 1991. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res 8:979-988.
23. Oh DM, Curl RL, Amidon GL. 1993. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: A mathematical model. Pharm Res 10:264-270.
24. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
25. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). 2000. Guidance for industry waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Rockville, Maryland: FDA.
26. Yazdanian M, Briggs K, Jankovsky C, Hawi A. 2004. The "high solubility' definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res 21:293-299.
27. Rinaki E, Dokoumetzidis A, Valsami G, Macheras P. 2004. Identification of biowaivers among Class II drugs: Theoretical justification and practical examples. Pharm Res 21:1567-1572.
28. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
29. European Medicines Agency (EMA). 2010. Evaluation of medicines for human use, CHMP. Guideline on the investigation of bioequivalence. London, UK: EMA.
30. Benet LZ, Broccatelli F, Oprea TI. 2011. BDDCS applied to over 900 drugs. AAPS J 13:519-547.
31. Broccatelli F, Cruciani G, Benet LZ, Oprea TI. 2012. BDDCS class prediction for new molecular entities. Mol Pharm 9:570-580.
32. Charkoftaki G, Dokoumetzidis A, Valsami G, Macheras P. 2012. Elucidating the role of dose in the biopharmaceutics classification of drugs: The concepts of critical dose, effective in vivo solubility, and dose-dependent BCS. Pharm Res 29:3188-3198.
33. Benet LZ. 2013. The role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System) in drug development. J Pharm Sci 102:34-42.
34. Van de Waterbeemd V, Lennernas H, Artursson P, Eds. 2003. Drug bioavailability. Estimation of solubility, permeability, absorption and bioavailability. Wiley-VCH, Weinheim, Germany.
35. Casey DL, Beihn RM, Digenis GA, Shabhu MB. 1976. Method for monitoring hard gelatin capsule disintegration times in humans using external scintigraphy. J Pharm Sci 65:1412-1413.
36. Digenis GA, Beihn RM, Theodorakis MC, Shambhu MB. 1977. Use of 99mTc-labeled triethylenetetramine-polystyrene resin for measuring the gastric emptying rate in humans. J Pharm Sci 66:442-443.
37. Weitschies W, Wilson CG. 2011. In vivo imaging of drug delivery systems in the GI tract. Int J Pharm 417:216-226.
38. Stefanio M, Locatelli I, Vrečer F, Sever T, Mrhar A, Bogataj M. 2012. The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: An in vitro/in vivo correlation. Eur J Pharm Biopharm 82:376-382.
39. Yuen KH. 2010. The transit of dosage forms through the small intestine. Int J Pharm 395:9-16.
40. Wilson GG. 2010. The transit of dosage forms through the colon. Int J Pharm 395:17-25.
41. Schiller C, Fröhlich CP, Giessmann T, Siegmund W, Mönnikes H, Hosten N, Weitschies W. 2005. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 22:971-979.
42. Dokoumetzidis A, Macheras P. 2008. IVIVC of controlled release formulations: Physiological-dynamical reasons for their failure. J Control Release 129:76-80.
43. Macheras P, Argyrakis P. 1997. GI drug absorption: Is it time to consider heterogeneity as well as homogeneity? Pharm Res 14:842-847.
44. Kopelman R. 1988. Fractal reaction kinetics. Science 241:1620-1626.
45. Cascone S, De Santis F, Lamberti G, Titomanlio G. 2011. The influence of dissolution conditions on the drug ADME phenomena. Eur J Pharm Biopharm 79:382-391.
46. Minekus PM, Havenaar R, Huis in't Veld JH. 1995. A multicompartmental dynamic computer-controlled model simulating the stomach and small intestine. Altern Lab Anim 23:197-209.
47. Tam YK, Anderson KE. 2000. Simulated biological dissolution and absorption system. Patent US6022733.
48. Wickham M, Faulks R. 2007 International Publication No. WO 2007/010238.
49. Rozga J, Demetriou A. 2002. Artificial gut. Patent US6379619. pp B1.
50. Garbacz G, Wedemeyer R, Nagel S, Giessmann T, Mönnikes H, Wilson C, Siegmund W, Weitschies W. 2008. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. Eur J Pharm Biopharm 70:421-428.
51. Bogataj M, Cof G, Mrhar A. 2010. Peristaltic movement simulating stirring device for dissolution testing. WO Patent WO/2010/014046.
52. Dokoumetzidis A, Macheras P. 1997. A population growth model of dissolution. Pharm Res 14:1122-1126.
53. Valsami G, Dokoumetzidis A, Macheras P. 1999. Modeling of supersaturated dissolution data. Int J Pharm 181:153-157.
54. Lánský P, Weiss M. 1999. Does the dose-solubility ratio affect the mean dissolution time of drugs? Pharm Res 16:1470-1476.
55. Rinaki E, Dokoumetzidis A, Macheras P. 2003. The mean dissolution time depends on the dose/solubility ratio. Pharm Res 20:406-408.
56. Dokoumetzidis A, Papadopoulou V, Macheras P. 2006. Analysis of dissolution data using modified versions of Noyes-Whitney equation and the weibull function. Pharm Res 23:256-261.
57. Cupera J, Lansky P. 2010. Random effects in drug dissolution. Eur J Pharm Sci 41:430-439.
58. Dokoumetzidis A, Macheras P. 2009. Fractional kinetics in drug absorption and disposition processes. J Pharmacokinet Pharmacodyn 36:165-178.
59. Kytariolos J, Dokoumetzidis A, Macheras P. 2010. Power law IVIVC: An application of fractional kinetics for drug release and absorption. Eur J Pharm Sci 41:299-304.
60. Dokoumetzidis A, Macheras P. 2011. The changing face of the rate concept in biopharmaceutical sciences: From classical to fractal and finally to fractional. Pharm Res 28:1229-1232.
61. Macheras P, Koupparis M, Antimisiaris S. 1989. Effect of temperature and fat content on the solubility of hydrochlorothiazide and chlorothiazide in milk. J Pharm Sci 78:933-936.
62. Macheras P, Koupparis M, Antimisiaris S. 1990. Drug binding and solubility in milk. Pharm Res 7:537-541.
63. Macheras P, Koupparis M, Tsaprounis C. 1986. Drug dissolution studies in milk using the automated flow-injection serial dynamic dialysis technique. Int J Pharm 33:125-136.
64. Macheras P, Koupparis M, Apostolleli E. 1987. Dissolution of four controlled-release theophylline formulations in milk. Int J Pharm 36:73-79.
65. Macheras P, Koupparis M, Antimisiaris S. 1989. An in vitro model for exploring CR theophylline-milk fat interactions. Int J Pharm 54:123-130.
66. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 15:698-705.
67. Reppas C, Vertzoni M. 2012. Biorelevant in-vitro performance testing of orally administered dosage forms. J Pharm Pharmacol 64:919-930.
68. Stuart M, Box K. 2005. Chasing equilibrium: Measuring the intrinsic solubility of weak acids and bases. Anal Chem 77:983-990.
69. Box KJ, Völgyi G, Baka E, Stuart M, Takács-Novák K, Comer JE. 2006. Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution-A validation study. J Pharm Sci 95:1298-1307.
70. Psachoulias D, Vertzoni M, Goumas K, Kalioras V, Beato S, Butler J, Reppas C. 2011. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res 28:3145-3158.
71. Psachoulias D, Vertzoni M, Butler J, Busby D, Symillides M, Dressman J, Reppas C. 2012. An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine. Pharm Res 29:3486-3498.
72. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J Pharm Sci 98:2549-2572.
73. Carlert S, Pålsson A, Hanisch G, von Corswant C, Nilsson C, Lindfors L, Lennernäs H, Abrahamsson B. 2010. Predicting intestinal precipitation-A case example for a basic BCS class II drug. Pharm Res 27:2119-2130.
74. Hsieh YL, Ilevbare GA, Van Eerdenbrugh B, Box KJ, Sanchez-Felix MV, Taylor LS. 2012. pH-Induced precipitation behavior of weakly basic compounds: Determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm Res 29:2738-2753.
75. Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. 2004. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol 56:43-51.
76. Clarysse S, Psachoulias D, Brouwers J, Tack J, Annaert P, Duchateau G, Reppas C, Augustijns P. 2009. Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs. Pharm Res 26:1456-1466.
77. Bonlokke L, Christensen FN, Knutson L, Kristensen HG, Lennernäs H. 1997. A new approach for direct in vivo dissolution studies of poorly soluble drugs. Pharm Res 14:1490-1492.
78. Dokoumetzidis A, Papadopoulou V, Valsami G, Macheras P. 2008. Development of a reaction-limited model of dissolution: Application to official dissolution tests experiments. Int J Pharm 355:114-125.
79. Charkoftaki G, Dokoumetzidis A, Valsami G, Macheras P. 2011. Supersaturated dissolution data and their interpretation: The TPGS-carbamazepine model case. J Pharm Pharmacol 63:352-361.
80. Charkoftaki G, Valsami G, Macheras P. 2012. From supersaturated drug delivery systems to the rising era of pediatric formulations. Chem Biochem Eng 26:427-434.
81. Lindfors L, Forssén S, Westergren J, Olsson U. 2008. Nucleation and crystal growth in supersaturated solutions of a model drug. J Colloid Interface Sci 325:404-413.
82. Sugano K. 2009. A simulation of oral absorption using classical nucleation theory. Int J Pharm 378:142-145.
83. Sugano K. 2010. Aqueous boundary layers related to oral absorption of a drug: From dissolution of a drug to carrier mediated transport and intestinal wall metabolism. Mol Pharm 7:1362-1373.
84. Scholz A, Kostewicz E, Abrahamsson B, Dressman JB. 2003. Can the USP paddle method be used to represent in-vivo hydrodynamics? J Pharm Pharmacol 55:443-451.
85. D'Arcy DM, Liu B, Corrigan O. 2011. Investigating the effect of solubility and density gradients on local hydrodynamics and drug dissolution in the USP 4 dissolution apparatus. Int J Pharm 419:175-185.
86. D'Arcy DM, Corrigan OI, Healy AM. 2006. Evaluation of hydrodynamics in the basket dissolution apparatus using computational fluid dynamics-dissolution rate implications. Eur J Pharm Sci 27:259-267.
87. D'Arcy DM, Healy AM, Corrigan OI. 2009. Towards determining appropriate hydrodynamic conditions for in vitro in vivo correlations using computational fluid dynamics. Eur J Pharm Sci 37:291-299.
88. Kakhi M. 2009. Mathematical modeling of the fluid dynamics in the flow-through cell. Int J Pharm 376:22-40.
89. Sheng JJ, Sirois PJ, Dressman JB, Amidon GL. 2008. Particle diffusional layer thickness in a USP dissolution apparatus II: A combined function of particle size and paddle speed. J Pharm Sci 97:4815-4829.
90. Wang Y, Abrahamsson B, Lindfors L, Brasseur JG. 2012. Comparison and analysis of theoretical models for diffusion-controlled dissolution. Mol Pharm 9:1052-1066.
91. Brunner L, Tolloczko S. 1900. Uber die auflosungsgeschwindindigkeit fester Korper. Z Phys Chem 35:283-290.
92. Hixson AW, Crowell JH. 1931. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem 23:923-931.
93. Macheras P, Dokoumetzidis A. 2000. On the heterogeneity of drug dissolution and release. Pharm Res 17:108-112.
94. Papadopoulou V, Kosmidis K, Vlachou M, Macheras P. 2006. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm 309:44-50.
95. Mueller P, Rudin D, Tien H, Wescott W. 1962. Reconstitution of cell membrane structure in vitro and its transformation into an existable system. Nature 194:979-980.
96. Avdeef A. 2005. High throughput measurement of permeability. In Drug bioavailability: Estimation of solubility, permeability and bioavailability; van de Waterbeemd H, Lennernas H, Artursson P, Eds. Weinheim, Germany: Willey-VCH, pp 46-71.
97. Walter A, Gutknecht J. 1984. Monocarboxylic acid permeation through lipid bilayer membranes. J Membr Biol 77:255-264.
98. Xiang TX, Anderson B. 1994. Substituent contributions to the transport of substituted p-toluic acids across lipid bilayer membranes. J Pharm Sci 83:1511-1518.
99. Ungell AL, Karlsson J. 2005. Cell cultures in drug discovery: An industrial perspective. In Drug bioavailability: Estimation of solubility, permeability and bioavailability; van de Waterbeemd H, Lennernas H, Artursson P, Eds. Weinheim, Germany: Willey-VCH, pp 90-131.
100. Balimane P, Chong S, Morrison R. 2004. Current methodologies used for evaluation of intestinal permeability and absorption. J Pharmacol Toxicol Methods 44:301-312.
101. Avdeef A. 2001. High-throughput measurements of solubility profiles. In Pharmacokinetic optimization in drug research; Testa B, van de Waterbeemd H, Folkers G, Guy R, Eds. Zurich: Verlag Helvetica Chimica Acta and Weinheim; Wiley-VCH, Weinheim, Germany, pp 305-326.
102. Avdeef A, Strafford M, Block E, Balogh M, Chambliss W, Khan I. 2001. Drug absorption in vitro model: Filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in Piper methysticum Forst. Eur J Pharm Sci 14:271-280.
103. Avdeef A. 2001. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 1:277-351.
104. Camenisch G, Alsenz J, van de Waterbeemd H, Folker G. 1998. Estimation of permeability by diffusion through Caco-2 cell monolayers using the drugś liphophilicity and molecular weight. Eur J Pharm Sci 6:313-319.
105. Palm K, Luthman K, Ros J, Gråsjö J, Artursson P. 1999. Effect of molecular charge on intestinal epithelial drug transport: pH-Dependent transport of cationic drugs. J Pharmacol Exp Ther 291:435-443.
106. Ungell AL. 1997. In vitro absorption studies and their relevance to absorption from the GI tract. Drug Dev Ind Pharm 23:879-892.
107. Taillardat-Bertschinger A, Marca Martinet CA, Carrupt PA, Reist M, Caron G, Fruttero R, Testa B. 2002. Molecular factors influencing retention on immobilized artificial membranes (IAM) compared to partitioning in liposomes and n-octanol. Pharm Res 19:729-737.
108. Pidgeon C, Ong S, Liu H, Qiu X, Pidgeon M, Dantzig AH, Munroe J, Hornback WJ, Kasher JS, Glunz L, Szczerba T. 1995. IAM chromatography: An in vitro screen for predicting drug membrane permeability. J Med Chem 38:590-594.
109. Liu XY, Nakamura C, Yang Q, Kamo N, Miyake J. 2002. Immobilized liposome chromatography to study drug-membrane interactions. Correlation with drug absorption in humans. J Chromatogr A 961:113-118.
110. Yen TE, Agatonovic-Kustrin S, Evans AM, Nation RL, Ryand J. 2005. Prediction of drug absorption based on immobilized artificial membrane (IAM) chromatography separation and calculated molecular descriptors. J Pharm Biomed Anal 38:472-478.
111. Kansy M, Senner F, Gubernator K. 1998. Physicochemical high throughput screening, parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007-1010.
112. Faller B. 2008. Artificial membrane assays to assess permeability. Current Drug Metabolism 9:886-892.
113. Fogh J, Fogh JM, Orfeo T. 1977. One hundred and twenty seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59:221-226.
114. Artursson P. 1990. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79:476-482.
115. Hidalgo IJ, Raub TJ, Borchardt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749.
116. Hilgers AR, Conradi RA, Burton PS. 1990. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 9:902-910.
117. Cho MJ, Thompson DP, Cramer CT, Vidmar TJ, Schieszka JF. 1989. The Madin-Darby canine kidney (MDCK) epithelial cell monolayers as a model cellular transport barrier. Pharm Res 6:71-77.
118. Covitz KMY, Amidon GL, Sadée W. 1996. Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharm Res 13:1631-1634.
119. Pinto M, Robine-Leon S, Appay MD, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Simon-Assmann P, Haffen K, Fogh J, Zweibaum A. 1983. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323-330.
120. Artursson P, Tavelin S. 2005. Caco-2 and emerging alternatives for prediction of intestinal drug transport: A general overview. In Drug bioavailability: Estimation of solubility, permeability and bioavailability; van de Waterbeemd H, Lennernas H, Artursson P, Eds. Weinheim, Germany: Willey-VCH, pp 72-90.
121. Wilson G, Hassan IF, Dix CJ, Williamson I, Mackay M. 1990. Transport and permeability properties of human Caco-2 cells. An in vitro model for the intestinal epithelial cell barrier. J Control Release 11:25-40.
122. Artursson P, Ungell AL, Löfroth JE. 1993. Selective paracellular permeability in two models for intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 10:1123-1129.
123. Artursson P, Palm K, Luthman K. 1996. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 22:67-84.
124. Hidalgo I, Li J. 1996. Carrier-mediated transport and efflux mechanisms in Caco-2 cells. Adv Drug Deliv Rev 22:53-66.
125. Flanagan S, Takahashi L, Liu X, Benet L. 2002. Contribution of saturable active secretion passive trancellular and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells. J Pharm Sci 91:1169-1177.
126. Engman H, Lennernas H, Taipalensuu J, Otter C, Leidvik B, Artursson P. 2001. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. J Pharm Sci 90:1736-1751.
127. Cummins C, Jacobsen W, Benet L. 2002. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharm Exp Ther 300:1036-1045.
128. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. 1999. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 62:25-31.
129. Cummins C, Mangravite L, Benet L. 2001. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res 18:1102-1109.
130. Collett A, Tanianis-Hughes J, Warhurst G. 2004. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: A possible source of transporter mediated drug interactions? Biochem Pharmacol 68:783-790.
131. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL. 2006. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: Comparison between human segments and Caco-2 cells. Eur J Pharm Sci 28:291-299.
132. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson JE. 2007. Expression of 36 drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340.
133. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, Kindmark A, Artursson P. 2006. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29:269-277.
134. Stenberg P, Norinder U, Luthman K, Artursson P. 2001. Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 44:1927-1937.
135. Sköld C, Winiwarter S, Wernevik J, Bergström F, Engström L, Allen R, Box K, Comer J, Mole J, Hallberg A, Lennernäs H, Lundstedt T, Ungell AL, Karlén A. 2006. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. J Med Chem 49:6660-6671.
136. Ekins S, Durst GL, Stratford RE, Thorner DA, Lewis R, Loncharich RJ, Wikel JH. 2001. Three-dimensional quantitative structure-permeability relationship analysis for series of inhibitors of rhinovirus replication. J Chem Inf Comput Sci 41:1578-1586.
137. Goodwin J, Condari R, Ho N, Burton P. 2001. Physicochemical determinants of passive membrane permeability: Role of solute hydrogen-bonding potential and volume. J Med Chem 44:3721-3729.
138. Liang E, Proudfoot J, Yazdanian M. 2000. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell mololayers. Pharm Res 17:1168-1174.
139. Grasset E, Pinto M, Dussaulx E, Zweibaum A. 1984. Epithelial properties of human colonic carcinoma cell line Caco-2; electrical parameters. Am J Physiol 247:C260-C267.
140. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88:28-33.
141. Rothen-Rutishauser B, Kraemer SD, Braun A, Guenthert M, Wunderli-Allenspach H. 1998. MDCK cell cultures as an epithelial in vitro model: Cytoskeleton and tight junctions as indicators for the definition of age-related stages by confocal microscopy. Pharm Res 15:964-971.
142. Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ. 2002. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology 64:126-134.
143. Evers R, Kool L, van Deemter H, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P. 1998. Drug export activity of the human canalicularmultispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310-1319.
144. Tang F, Horic K, Borchardt R. 2002. Are MDCK cells transfected with the human MRP2 gene a good model for human intestinal mucosa? Pharm Res 19:773-779.
145. König J, Rost D, Cui Y, Keppler D. 1999. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29:1156-1163.
146. Zhang Y, Benet LZ. 2001. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokin 40:159-168.
147. Kristl A. 2009. Membrane permeability in the GI tract: The interplay between microclimate pH and transporters. Chem Biodiver 6:1923-1942.
148. Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, Sugiyama Y. 2010. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 27:442-446.
149. Dressman J, Fleisher D. 1986. Mixing-tank model for predicting dissolution rate control or oral absorption. J Pharm Sci 75:109-116.
150. Yu LX, Crison JR, Amidon GL. 1996. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 10:111-118.
151. Grass GM. 1997. Simulation models to predict oral drug absorption from in vitro data. Adv Drug Deliv Rev 23:199-219.
152. Yu LX, Amidon GL. 1999. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186:119-125.
153. Agoram B, Woltasz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50:S41-S67.
154. Ni PF, Ho NFH, Fox JL, Leuenberger H, Higuchi WI. 1980. Theoretical-model studies of intestinal drug absorption. V. Non-steady-state fluid-flow and absorption. Int J Pharm 5:33-47.
155. Willmann S, Schmitt W, Keldenich J, Dressmann JB. 2003. A physiologic model for simulating GI flow and drug absorption in rats. Pharm Res 20:1766-1771.
156. Kalampokis A, Argyrakis P, Macheras P. 1999. A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts. Pharm Res 16:1764-1769.
157. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:4-25.
158. Stenberg P, Bergström CA, Luthman K, Artursson P. 2002. Theoretical predictions of drug absorption in drug discovery and development. Clin Pharmacokinet 41:877-899.
159. Bergström CA, Strafford M, Lazorova L, Avdeef A, Luthman K, Artursson P. 2003. Absorption classification of oral drugs based on molecular surface properties. J Med Chem 46:558-570.
160. Van de Waterbeemd H, Jones B. 2003. Predicting oral absorption and bioavailability. Prog Med Chem 41:1-59.
161. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Butina D, Beck G, Sherborne B, Cooper I, Platts JA. 2001. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 90:749-784.
162. Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I. 2002. Rate-limited steps of human oral absorption and QSAR studies. Pharm Res 19:1446-1457.
163. Turner JV, Maddalena DJ, Agatonovic-Kustrin S. 2004. Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharm Res 21:68-82.
164. Midha KK, McKay G. 2009. Bioequivalence: Its history, practice and future. AAPS J 11:664-670.
165. Skelly JP. 2010. A history of biopharmaceutics in the Food and Drug Administration. AAPS J 12:44-50.
166. 21 C.F.R. Part 320-Bioavailability and bioequivalence requirements title 21-Food and drugs.
167. Federal Register. 1969. Federal Register 34:2673.
168. Federal Register. 1970. Federal Register 35:6574.
169. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). 2003. Bioavailability and bioequivalence studies for orally administered drug products. General Considerations. Rockville, Maryland: FDA.
170. Bois FY, Tozer TN, Hauck WW, Chen ML, Patnaik R, Williams RL. 1994. Bioequivalence: Performance of several measures of extent of absorption. Pharm Res 11:715-722.
171. Bois FY, Tozer TN, Hauck WW, Chen ML, Patnaik R, Williams RL. 1994. Bioequivalence: Performance of several measures of rate of absorption. Pharm Res 11:966-974.
172. Chen ML, Lesko LJ, Williams RL. 2001. Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet 40:565-572.
173. Macheras P, Symillides M, Reppas C. 1996. An improved intercept method for the assessment of absorption rate in bioequivalence studies. Pharm Res 13:1755-1758.
174. max/AUC is an effective metric in investigations of bioequivalence. Pharm Res 12:937-942.
175. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). 2001. Statistical approaches to establishing bioequivalence. Rockville, Maryland: FDA.
176. Midha K, Rawson M, Hubbard J. 1998. Bioequivalence: Switchability and scaling. Eur J Pharm Sci 6:87-91.
177. McGilveray IJ, Midha KK, Skelly JP, Dighe S, Doluisio JT, French IW, Karim A, Burford R. 1990. Consensus report from "Bio-International '89': Issues in the evaluation of bioavailability data. J Pharm Sci 79:945-946.
178. Blume HH, McGilveray IJ, Midha KK. 1995. Bio-International 94, Conference on bioavailability, bioequivalence and pharmacokinetic studies. Eur J Pharm Sci 3:113-124.
179. Blume HH, Midha KK. 1993. Bio-international '92, Conference on bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 11:1186-1189.
180. Shah VP, Yacobi A, Barr WH, Benet LZ, Breimer D, Dobrinska MR, Endrenyi L, Fairweather W, Gillespie W, Gonzalez MA, Hooper J, Jackson A, Lesko LJ, Midha KK, Noonan PK, Patnaik R, Williams RL. 1996. Absorption of orally administered highly variable drugs and drug formulations. Pharm Res 13:1590-1594.
181. European Medicines Agency (EMA). 2001. Evaluation of Medicines for Human Use, CPMP. Note for GUIDANCE on the investigation of bioavailability and bioequivalence, London, UK: EMA.
182. max. Int J Clin Pharmacol Ther 41:217-225.
183. Boddy AW, Snikeris FC, Kringle RO, Wei GC, Oppermann JA, Midha KK. 1995. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs. Pharm Res 12:1865-1868.
184. Tothfalusi L, Endrenyi L. 2003. Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm Res 20:382-389.
185. Karalis V, Symillides M, Macheras P. 2004. Novel scaled average bioequivalence limits based on GMR and variability considerations. Pharm Res 21:1933-1942.
186. Karalis V, Macheras P, Symillides M. 2005. Geometric mean ratio dependent scaled bioequivalence limits with leveling-off properties. Eur J Pharm Sci 26:54-61.
187. Kytariolos J, Karalis V, Macheras P, Symillides M. 2006. Novel scaled bioequivalence limits with leveling-off properties. Pharm Res 23:2657-2664.
188. Tothfalusi L, Endrenyi L, Arieta AG. 2009. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet 48:725-743.
189. Food and Drug Administration (FDA). 2011. Office of Generic Drugs, Draft Guidance for Industry on Bioequivalence Recommendations for Progesterone Capsules.Rockville, Maryland: FDA.
190. Haidar SH, Davit B, Chen ML, Conner D, Lee L, Li QH, Lionberger R, Makhlouf F, Patel D, Schuirmann DJ, Yu LX. 2008. Bioequivalence approaches for highly variable drugs and drug products. Pharm Res 15:237-241.
191. Haidar SH, Makhlouf F, Schuirmann DJ, Hyslop T, Davit B, Conner D, Yu LX. 2008. Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J 10:450-454.
192. Davit B. 2006. Highly variable drugs bioequivalence issues: FDA proposal under consideration. Meeting of FDA Committee for Pharmaceutical Science. Rockville, Maryland: FDA.
193. Davit B. 2007. Highly variable drugs-Bioequivalence issues: FDA proposal under consideration. AAPS/FDA Workshop on BE, BCS, and Beyond. North Bethesda, Maryland: FDA.
194. Davit B. 2011. Highly variable drugs: Reference-scaled average bioequivalence and sequential design studies. AAPS Workshop on Facilitating Oral Product Development and Reducing Regulatory Burden through Novel Approaches to Assess Bioavailability/Bioequivalence. Washington DC.
195. Karalis V, Symillides M, Macheras P. 2011. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline. Eur J Pharm Sci 44:497-505.
196. Karalis V, Symillides M, Macheras P. 2012. Bioequivalence of highly variable drugs: A comparison of the newly proposed regulatory approaches by FDA and EMA. Pharm Res 29:1066-1077.
197. Chen ML, Amidon GL, Benet LZ, Lennernas H, Yu LX. 2011. The BCS, BDDCS, and regulatory guidances. Pharm Res 28:1774-1778.
198. Custodio J, Wu C, Benet L. 2008. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60:717-733.
199. Benet L. 2010. Predicting drug disposition via application of a biopharmaceutics drug disposition classification system. Basic Clin Pharmacol Toxicol 106:162-167.
200. Benet LZ, Amidon GL, Barends DM, Lennernäs H, Polli JE, Shah VP, Stavchansky SA, Yu LX. 2008. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 25:483-488.
201. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). 1997. Guidance for industry. Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. Rockville, Maryland: FDA.
202. Rinaki E, Valsami G, Macheras P. 2003. Quantitative Biopharmaceutics Classification System: The central role of dose/solubility ratio. Pharm Res 20:1917-1925.
203. Yalkowsky SH, Johnson JL, Sanghvi T, Machatha SG. 2006. A 'rule of unity' for human intestinal absorption. Pharm Res 23:2475-2481.
204. Papadopoulou V, Valsami G, Dokoumetzidis A, Macheras P. 2008. Biopharmaceutics Classification Systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples. Int J Pharm 361:70-77.
205. Zakeri-Milani P, Barzegar-Jalali M, Azimi M, Valizadeh H. 2009. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur J Pharm Biopharm 73:102-106.
206. Box K, Comer J. 2008. Using measured pKa, log P and solubility to investigate supersaturation and predict BCS Class. Curr Drug Metabol 9:869-878.
207. Khandelwal A, Bahadduri PM, Chang C, Polli JE, Swaan PW, Ekins S. 2007. Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res 24:2249-2262.
208. Benet LZ, Larregieu CA. 2010. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin Pharmacol Ther 88:405-407.
209. European Medicines Agency (EMA). 1995. Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents. CPMP/EWP/239/95 final.
210. Food and Drug Administration (FDA). 2007. Draft Guidance on Mesalamine, Suppository/Rectal.
211. Food and Drug Administration (FDA). 2008. Draft Guidance on Mesalamine, Enema /Rectal. Rockville, Maryland: FDA.
212. Food and Drug Administration (FDA). 2012. Draft Guidance on Mesalamine, Delayed Release Tablet/Oral. Rockville, Maryland: FDA.
213. Food and Drug Administration (FDA). 2012. Draft Guidance on Mesalamine, Extended Release Capsule/Oral. Rockville, Maryland: FDA.
214. Yan Y, Faustino PJ, Volpe DA, Lyon RC, Yu LX. 2007. Biopharmaceutics classification of selected beta-blockers: Solubility and permeability class membership. Mol Pharm 4:608-614.
215. Chen ML, Yu L. 2009. The use of drug metabolism for prediction of intestinal permeability. Mol Pharm 6:74-81.
216. Rinaki E, Valsami G, Macheras P. 2003. The power law can describe the 'entire' drug release curve from HPMC-based matrix tablets: A hypothesis. Int J Pharm 255:199-207.
217. World Health Organization. 2006. Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms. WHO Technical Report Series, No. 937.
218. Zhang N, Yang J, Chow SC, Endrenyi L, Chi E. 2013. Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics. Stat Med 32:424-433.